

Ancobon (flucytosine)

Override(s)	Approval Duration
Prior Authorization	1 year

Medications
Ancobon (flucytosine)

APPROVAL CRITERIA

Requests for Ancobon (flucytosine) may be approved when the following criteria are met:

- I. Individual has a diagnosis of one of the following:
 - A. Serious *Candida* infection, including urinary tract or pulmonary infections, candidemia, endocarditis, meningitis and endophthalmitis; **OR**
 - B. Serious cryptococcal infections, including pulmonary infections, septicemia and meningitis; **OR**

AND

- II. Ancobon (flucytosine) will be used in combination with amphotericin B;

OR

- III. Individual is using alone or in combination with other antifungals for treatment of chromoblastomycosis (chromomycosis) caused by various dematiaceous fungi (such as *Cladosporium*, *Exophiala*, *Phialophora*) (AHFS);

OR

- IV. Individual is using for induction therapy for the treatment of acute infection of cryptococcal meningitis in HIV-infected individuals (DrugPoints B11a,);

AND

- V. Individual is using in combination with one of the following:
 - A. Amphotericin B; **OR**
 - B. Fluconazole;

OR

- VI. Individual is transitioning from inpatient treatment to an outpatient setting and requires continued therapy for an organism susceptible to Ancobon.

Ancobon (flucytosine) may not be approved for the following:

- I. Individual with known complete dihydropyrimidine dehydrogenase (DPD) enzyme deficiency.

Note:

Ancobon (flucytosine) has a black box warning indicating that use should be approached with extreme caution in individuals with impaired renal function. Close monitoring of hematologic, renal and hepatic status of all individuals is essential.

Key References:

1. Centers for Disease Control and Prevention (CDC). Fungal Diseases. Mucormycosis. Available at: <https://www.cdc.gov/fungal/diseases/mucormycosis/health-professionals.html>. Last Reviewed: May 27, 2020. Accessed: October 8, 2022.
2. Centers for Disease Control and Prevention (CDC). Sexually Transmitted Infection Treatment Guidelines, 2021. Available at <https://www.cdc.gov/std/treatment-guidelines/toc.htm>. Accessed: October 9, 2022.
3. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Accessed: October 8, 2022.
4. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
5. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2022; Updated periodically.
6. Panel on Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: recommendations from the Centers for Disease Control and Prevention (CDC), the National Institutes of Health (NIH), and the HIV Medicine Association of the Infectious Disease Society of America (IDSA). Available at <https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/whats-new>. Accessed: October 9, 2022.
7. Panel on Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Guidelines for the prevention and treatment of opportunistic infections in HIV-Exposed and HIV-Infected Children. Department of Health and Human Services. Available at <https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-pediatric-opportunistic-infections/whats-new-guidelines>. Accessed: October 9, 2022.
8. Pappas PG, Kauffman CA, Andes D, et al. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. *Clin Infect Dis*. 2016; 62(4):E1-50.

Federal and state laws or requirements, contract language, and Plan utilization management programs or policies may take precedence over the application of this clinical criteria.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.